What is Aobiome?
Aobiome operates at the vanguard of microbiome-based medicine, focusing on the therapeutic potential of Ammonia Oxidizing Bacteria to restore biological homeostasis. The company's market position is defined by its innovative approach to treating chronic conditions such as acne, eczema, rosacea, and hypertension. By repopulating beneficial bacteria on the skin, Aobiome aims to modulate the immune system and address unmet clinical needs that traditional pharmacological interventions often fail to resolve. Their research extends beyond dermatology into preclinical programs for pulmonary and gastrointestinal health, positioning the firm as a versatile player in the burgeoning field of microbiome therapeutics and personalized health management.
How much funding has Aobiome raised?
Aobiome has raised a total of $33.7M across 4 funding rounds:
Private Equity
$630K
Private Equity
$576K
Private Equity
$2.5M
Private Equity
$30M
Private Equity (2013): $630K, investors not publicly disclosed
Private Equity (2014): $576K, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Private Equity (2017): $30M featuring iCarbonX
Key Investors in Aobiome
iCarbonX
Digital health pioneer iCarbonX is creating the new global standard for health, wellness and healthcare by building the platform for digitizing, analyzing, and understanding life.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Aobiome?
With this latest round of financing, Aobiome is well-positioned to transition its lead product candidates through advanced clinical trials and potentially toward commercialization. The strategic focus will likely shift toward scaling manufacturing capabilities for its AOB-based therapies and expanding its multi-omics research initiatives. As the company matures, the integration of artificial intelligence and digital health data—facilitated by its strategic partnerships—will be instrumental in refining patient outcomes and optimizing therapeutic delivery. Investors are closely monitoring the firm's ability to translate its preclinical successes into validated clinical endpoints, which will be the primary driver for future valuation growth and potential market entry in the competitive landscape of inflammatory disease management.
See full Aobiome company page
